Background: In the U.S., the overall prevalence of HCV is 1.6% with a higher prevalence among African-Americans, people born between 1945 and 1965, and those with a history of injection drug use. Left untreated, chronic HCV infection can cause liver cirrhosis, liver failure and hepatocellular carcinoma (HCC). The risk of cirrhosis is 5-30% within 20 years of infection, and the risk of HCC in patients with cirrhosis is 2-4% per year. The Alabama Coalition for Testing, Interventions, and Engagement in HCV Care (ACTIVE-C), is a targeted collaboration among academic departments (UAB and UA), community clinics (FQHC and primary care clinics), emergency departments, and State and Public Health Departments in Alabama. ACTIVE-C is comprehensive network of university-based, community-based, and public health department-based testing, evaluation, and treatment faculty and providers who are collaborating to bring state-of-the-art care in primary care settings to those most in need of HCV treatment in Alabama. Methods: The project will be conducted in three phases, serving the target populations in Birmingham, Montgomery, Tuscaloosa, Huntsville and Mobile. In Phase 1, will expand treatment capacity within the regional partners, including education and training; establish data collection and management systems; and build capacity for HCV testing. In Phase 2, the implementation of HCV testing in primary care and ER settings will start. During this phase, building capacity for HCV treatment throughout the Network is a key priority. In Phase 3, treatment uptake and sustained virologic response (SVR) statewide will be tracked. Discussion: Over 1 year, it is anticipated that at least 18,000 people will be screened for HCV during the project period with over 1,300 HCV Ab reactive persons identified and with an estimated 750 persons with chronic HCV infection linked to care for potential curative treatment. Plans include ongoing expansion throughout Alabama in the future.